<DOC>
	<DOCNO>NCT00952692</DOCNO>
	<brief_summary>This phase I/II study determine safety gain insight immune response immunologic agent dHER2+AS15 ASCI administer combination lapatinib . This study patient metastatic breast cancer ( invasive breast cancer stage IV disease ) overexpresses HER2 resistant trastuzumab ( Herceptin ) . The dHER2 + AS15 candidate Antigen-Specific Cancer Immunotherapeutic ( ASCI ) contain recombinant protein term dHER2 , truncate version HER2 protein . HER2 protein commonly overexpressed breast cancer . This protein combine immunological adjuvant AS15 Adjuvant System GSK ( GlaxoSmithKline ) , liposomal formulation contain three immunostimulatory component . Lapatinib FDA approve use combination capecitabine treatment subject advance metastatic breast cancer whose tumor overexpress HER2 .</brief_summary>
	<brief_title>Study Assess dHER2+AS15 Cancer Vaccine Given Combination With Lapatinib Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>The following criterion check time study entry . The patient may include study ALL following statement FULLFILLED : 1 . The patient ( male female ) least 18 year old time signature inform consent form . 2 . Written inform consent obtain patient prior performance protocolspecific procedure . 3 . The patient diagnose confirm invasive breast cancer stage IV disease . Note : If metastatic disease restrict solitary lesion , neoplastic nature confirm cytology histology . 4 . The patient document disease progression relapse follow least one prior standard therapy trastuzumab ( alone combination chemotherapy ) . Patients prior lapatinib use eligible . Furthermore , The administration chemotherapeutic agent ( ) stop least 28 day time first ASCI administration . The administration trastuzumab alone could maintain chemotherapy , last dose trastuzumab give less three week first ASCI administration . The patient give trastuzumab trial . 5 . For metastatic patient whose disease ER+ and/or PR+ follow criterion meet : Patients visceral disease require chemotherapy ( eg. , patient liver lung metastasis ) . Rapidly progress life threaten disease , determine investigator . Patients receive hormonal therapy longer benefit therapy . 6 . A tumor lesion patient biopsied screening show either : Overexpression HER2 protein , determine immunohistochemistry ( IHC , result IHC 3+ ) Amplification HER2 gene determine FISH ( least 4 fold i.e . least 8 copy ) . Note : Overexpression/amplification measurement must perform metastatic lesion case lesion sufficiently easily accessible . If however biopsy possible , measurement perform primary tumor . Use primary tumor document justified . Ten FFPE tissue section tumor HER2 overexpression/amplification do availablemay request . These may use retrospectively carry part translational research ( i.e . analysis EGF receptor activity presence immune effector cell , refer Section 7 ) . 7 . The patient least one measurable lesion accord RECIST criterion . 8 . The patient ECOG status 0 1 . 9 . The patient adequate bone marrow reserve indicate : White blood cell count &gt; /= 3,000/mm3 . Neutrophil count &gt; /= 1,500/mm3 . Platelet count &gt; /= 100,000/mm3 . Hemoglobin level &gt; /= 10.0 g/dl . 10 . The patient adequate renal function show creatinine level ( i.e . within normal range ) . 11 . The patient adequate hepatic function show serum bilirubin level i.e : Serum bilirubin level within normal limit . Both AST ALT level &lt; 1.5 time ULN . Note : However , patient liver metastasis , serum bilirubin level &lt; 1.5 time ULN AST ALT level &lt; 3 time ULN accept . 12 . The patient baseline Left Ventricular Ejection Fraction ( LVEF ) measure MUGA scan equal great LLN radiology facility . 13 . If patient female , must nonchildbearing potential , i.e . current tubal ligation , hysterectomy , ovariectomy postmenopausal , childbearing potential , must practice adequate contraception 30 day prior treatment , negative pregnancy test continue precaution two month completion study treatment . Adequate contraception define contraceptive method failure rate le 1 % per year use consistently correctly ( applicable , mentioned product label ) example abstinence , combine progestogen oral contraceptive , injectable progestogen , implant levonorgestrel , oestrogenic vaginal ring , percutaneous contraceptive patch intrauterine device ( IUD ) intrauterine system ( IUS ) , vasectomy document azoospermia sole male partner double barrier method ( condom occlusive cap plus spermicidal agent ) . For azoospermia , `` document '' refers outcome investigator's/ designee 's medical examination subject review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record . Postmenopause : Menopause age associate complete cessation menstrual cycle , menses , implies loss reproductive potential ovarian failure . A practical definition accepts menopause 1 year without menses appropriate clinical profile appropriate age e.g . &gt; 45 year . 14 . Able swallow retain oral medication . 15 . In view investigator , patient comply requirement protocol . The following criterion check time study entry . If apply , patient must include study : 1 . The patient receive &gt; 300 mg/m2 doxorubicin ( cumulative dose ) &gt; 600 mg/m2 epirubicin ( cumulative dose ) . 2 . The patient receive treatment bisphosphonate UNLESS biphosphonate treatment initiate three week first ASCI administration . ( See also section 5.3.2. ) . 3 . The patient receive investigational nonregistered product ( drug vaccine ) study treatment ( ) within 30 day precede first dose study treatment , plan use study period . 4 . The patient currently receive amiodarone receive amiodarone 6 month prior screen . 5 . The patient require concomitant treatment systemic corticosteroid immunosuppressive agent . The use prednisone , equivalent , &lt; 0.5 mg/kg/day ( absolute maximum 40 mg/day ) , inhaled corticosteroid topical steroid permit . 6 . The patient malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . 7 . Patients ulcerative colitis . 8 . The patient know coronary artery disease , arrhythmia require treatment , clinically significant valvular disease , cardiomegaly chest Xray , ventricular hypertrophy ( find ECG ) previous myocardial infarction . 9 . The patient acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . 10 . The patient current active hepatic biliary 's disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) . 11 . The patient present autoimmune disease ( vitiligo autoimmune thyroid disease exclusion criterion ) . 12 . The patient know family history congenital hereditary immunodeficiency . 13 . The patient uncontrolled bleed disorder coagulation disorder thrombocytopenia prothrombotic disorder . 14 . The patient history anaphylaxis severe allergic reaction vaccine unknown allergen . 15 . The patient know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate Lapatinib . These include anilinoquinazolines , gefitinib ( Iressa ) , erlotinib ( Tarceva ) , chemically related compound excipients . 16 . The patient know positive Human Immunodeficiency Virus ( HIV ) . 17 . The patient ( ) previous concomitant malignancy sit except effectively treat : Nonmelanoma skin cancer carcinoma situ cervix Malignancy remission &gt; 2 year consider highly likely cure . 18 . The patient psychiatric addictive disorder may compromise ability give informed consent , comply trial procedure . 19 . The patient condition opinion investigator might jeopardize patient 's safety ability comply requirement study . 20 . The patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>dHER2 ASCI</keyword>
	<keyword>overexpressing HER2</keyword>
	<keyword>refractory trastuzumab</keyword>
</DOC>